Journal article
Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus
- Abstract:
-
Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on new-onset diabetes, glycemia and weight remains unclear.We studied the effects of the PCSK9 inhibitor evolocumab on fasting plasma glucose [FPG], glycated hemoglobin (HbA1c), weight and new-onset diabetes mellitus. We pooled 1-year (48-week) data for participants who had completed an evolocumab parent study before entering an open-label extension (OLE) trial. Data were available for 4,802 participants...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 1.0MB)
-
- Publisher copy:
- 10.1016/j.amjcard.2017.07.047
Authors
Funding
Amgen Inc.
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- American Journal of Cardiology Journal website
- Volume:
- 120
- Issue:
- 9
- Pages:
- 1521-1527
- Publication date:
- 2017-07-31
- Acceptance date:
- 2017-07-21
- DOI:
- EISSN:
-
1879-1913
- ISSN:
-
0002-9149
- Source identifiers:
-
710879
Item Description
- Keywords:
- Pubs id:
-
pubs:710879
- UUID:
-
uuid:18f08523-bed9-4470-bb04-11e18a4c0abe
- Local pid:
- pubs:710879
- Deposit date:
- 2017-08-07
Terms of use
- Copyright holder:
- Elsevier Inc
- Copyright date:
- 2017
- Notes:
- Copyright © 2017 Elsevier Inc. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.amjcard.2017.07.047
If you are the owner of this record, you can report an update to it here: Report update to this record